KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) Invested Capital (2016 - 2026)

Biogen has reported Invested Capital over the past 18 years, most recently at $24.9 billion for Q1 2026.

  • For Q1 2026, Invested Capital rose 15.85% year-over-year to $24.9 billion; the TTM value through Mar 2026 reached $24.9 billion, up 15.85%, while the annual FY2025 figure was $24.5 billion, 15.43% up from the prior year.
  • Invested Capital for Q1 2026 was $24.9 billion at Biogen, up from $24.5 billion in the prior quarter.
  • Over five years, Invested Capital peaked at $24.9 billion in Q1 2026 and troughed at $6.3 billion in Q3 2025.
  • A 5-year average of $20.3 billion and a median of $21.3 billion in 2024 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: crashed 69.69% in 2025 and later rose 15.85% in 2026.
  • Year by year, Invested Capital stood at $19.7 billion in 2022, then grew by 9.75% to $21.6 billion in 2023, then dropped by 1.5% to $21.3 billion in 2024, then increased by 15.43% to $24.5 billion in 2025, then rose by 1.62% to $24.9 billion in 2026.
  • Business Quant data shows Invested Capital for BIIB at $24.9 billion in Q1 2026, $24.5 billion in Q4 2025, and $6.3 billion in Q3 2025.